Antigen News and Research

RSS

UNOS policy change reduces disparities in kidney transplants for African-Americans

A national transplant policy change designed to give African-American patients greater access to donor kidneys has sliced in half the racial disparities that have long characterized the allocation of lifesaving organs, new Johns Hopkins research suggests.

2 Aug 2011

Kadmon, Dyax enter license agreement for antibody phage display libraries

Dyax Corp. and Kadmon Corporation, LLC announced today that Dyax has granted Kadmon a non-exclusive license to Dyax's proprietary "gold-standard" antibody phage display libraries for the discovery and development of therapeutic antibodies.

26 Jul 2011

Adaptimmune announces opening of pilot clinical trial in synovial sarcoma

Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.

25 Jul 2011

Access to kidney transplantation for minorities improves on elimination of allocation policy

A new study published in the American Journal of Transplantation reveals that since the elimination of the kidney allocation priority for matching for HLA-B on May 7, 2003, access to kidney transplantation for minorities has been improved. Improvement is a result of a policy that reduced the requirements for tissue matching.

22 Jul 2011

Skin dendritic cells promote distinct and opposing antigen-specific responses

A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same type of infection.

22 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States.

22 Jul 2011

WHO warns against blood test kits for tuberculosis

According to a World Health Organization (WHO) warning Sunday, the widely used blood tests to detect tuberculosis (TB) are “dangerous” to patients because they are unreliable and can produce incorrect results. The WHO announced that it will issue an unprecedented recommendation against using such tests for the infectious lung disease that affects some 14 million people worldwide. As much as a third of the world's population is thought to harbor the bacteria that cause TB.

21 Jul 2011

Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results

NanoBio Corporation announced today that data from its ferret influenza vaccine study of NB-1008 have been published in the July 2011 issue of Clinical Vaccine Immunology by the American Society of Microbiology.

21 Jul 2011

Experts present new research at 2011 Alzheimer's Association ICAD

Experts from the Center of Excellence on Brain Aging at NYU Langone Medical Center will present new research at the 2011 Alzheimer's Association International Conference on Alzheimer's disease to be held in Paris, France from July 16 - 21.

21 Jul 2011

Gene-based test for distinguishing harmless from precancerous pancreatic cysts

Johns Hopkins scientists have developed a gene-based test to distinguish harmless from precancerous pancreatic cysts. The test may eventually help some patients avoid needless surgery to remove the harmless variety.

21 Jul 2011

Emory-led consortium receives NIH grant to develop effective HIV/AIDS vaccine

A consortium of leading vaccine researchers at Emory University and partner institutions has received a National Institutes of Health (NIH) grant aimed at developing an effective HIV/AIDS vaccine.

19 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

Men with early-stage prostate cancer can benefit from short-term ADT, radiation therapy

Short-term hormone therapy given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in the July 14 issue of the New England Journal of Medicine.

14 Jul 2011

EC approves YERVOY for treatment of previously-treated advanced melanoma

Bristol-Myers Squibb today announced that the European Commission has approved YERVOY for the treatment of adult patients with previously-treated advanced melanoma.

14 Jul 2011

UIC study reveals potential of lycopene in prostate cancer prevention among African American men

Lycopene, a red pigment that gives tomatoes and certain other fruits and vegetables their color, could help prevent prostate cancer, especially in African American men, according to new research at the University of Illinois at Chicago.

14 Jul 2011

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

PharmAthene, Inc. announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay.

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

Blood cancer drug trial results questioned by FDA

U.S. drug reviewers might limit the use of a Seattle Genetics Inc’s experimental blood cancer drug due to the narrow scope of its clinical trials. According to papers released Tuesday by the Food and Drug Administration (FDA), it requests an advisory panel to consider the drug, under the proposed trade name Adcetris known chemically as brentuximab vedotin, for use in previously treated patients with Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL).

13 Jul 2011